Literature DB >> 1909141

Tumor necrosis factor-alpha: central regulatory cytokine in the induction of macrophage antimicrobial activities.

C A Nacy1, A I Meierovics, M Belosevic, S J Green.   

Abstract

Expression of activated macrophage resistance to infection requires the cooperative interaction of interferon-gamma (IFN-gamma) and either interleukin-2 (IL-2), interleukin-4 or granulocyte/macrophage-colony-stimulating factor: no single cytokine is effective. For IFN-gamma and IL-2, the effector activity can be suppressed by the presence of anti-tumor necrosis factor-alpha (TNF-alpha) antibodies in the reaction mixture. IFN-gamma and IL-2, only in combination, induce TNF-alpha-specific mRNA and secretion of this cytokine by macrophages. Development of intracellular killing activity by activated macrophages also requires the autocrine effects of TNF-alpha. IFN-gamma provides the first signal for the production of nitric oxide (NO), the effector molecule for intracellular destruction of parasites. When IFN-gamma-treated cells are infected with pathogens, they are stimulated to make TNF-alpha. Expression of intracellular killing, as well as production of NO, is inhibited by anti-TNF-alpha antibody.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1909141     DOI: 10.1159/000163640

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  17 in total

1.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Monocytes of individual human subjects display heterogeneous bacterial uptake and antilisterial activity.

Authors:  G Zerlauth; H E Chehadeh; E Maier; Z Schaff; M M Eibl; J W Mannhalter
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis.

Authors:  A Wellmer; J Gerber; J Ragheb; G Zysk; T Kunst; A Smirnov; W Brück; R Nau
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

4.  Expression of tumor necrosis factor and c-fos genes in peritoneal macrophages of hypothyroid mice.

Authors:  W K Liu
Journal:  Inflammation       Date:  1993-04       Impact factor: 4.092

5.  Does inhibition of tumor necrosis factor alpha affect chlamydial genital tract infection in mice and guinea pigs?

Authors:  T Darville; C W Andrews; R G Rank
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

6.  Interleukin-10 modulates proinflammatory cytokines in the human monocytic cell line THP-1 stimulated with Borrelia burgdorferi lipoproteins.

Authors:  P K Murthy; V A Dennis; B L Lasater; M T Philipp
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

7.  Growth hormone activation of human monocytes for superoxide production but not tumor necrosis factor production, cell adherence, or action against Mycobacterium tuberculosis.

Authors:  J Warwick-Davies; D B Lowrie; P J Cole
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

8.  Down-regulation of tumor necrosis factor alpha activity by acute ethanol treatment in human peripheral blood monocytes.

Authors:  B K Verma; M Fogarasi; G Szabo
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

9.  Entamoeba histolytica modulates the nitric oxide synthase gene and nitric oxide production by macrophages for cytotoxicity against amoebae and tumour cells.

Authors:  W Wang; K Keller; K Chadee
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

10.  Interferon-gamma-dependent inhibition of late allergic airway responses and eosinophilia by CD8+ gammadelta T cells.

Authors:  Susumu Isogai; Aravind Athiviraham; Russell S Fraser; Rame Taha; Qutayba Hamid; James G Martin
Journal:  Immunology       Date:  2007-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.